search
Back to results

Intravenous Estrogen in Kidney Transplant Study (PERT)

Primary Purpose

Ischemia Reperfusion Injury

Status
Active
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
Conjugated Estrogen
Normal saline
Sponsored by
University of Pennsylvania
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Ischemia Reperfusion Injury

Eligibility Criteria

21 Years - undefined (Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  1. Female gender
  2. Age > 21 years at time of transplant
  3. Pre-existing dialysis dependence of at least 1-months duration at the time of transplant
  4. Receiving a deceased donor renal transplant with KDPI >40
  5. Written informed consent obtained from subject and ability for subject to comply with the requirements of the study

Exclusion Criteria:

  1. History of solid organ transplant
  2. Receiving a combined heart-kidney transplant, liver-kidney transplant, or other multi- visceral organ transplant
  3. Personal history of deep vein thrombosis (DVT) or pulmonary embolism (PE)
  4. Personal history of hypercoagulable condition including but not limited to Lupus Anticoagulant, Leiden Factor V Mutation, Prothrombin Gene Mutation, Protein C or S deficiency, or any other hypercoagulable condition considered by the attending transplant surgeon on clinical service or Data and Safety Monitoring Board (DSMB) t to warrant exclusion from the study
  5. Personal history of an estrogen sensitive cancer (breast, endometrial, ovarian)
  6. Personal history of arterial thromboembolic disease such as stroke or myocardial infarction in the 6 months prior to transplantation
  7. Patient already on estrogen (including oral contraceptive pills) or anti-estrogen therapy for other indications
  8. Patient who is expected to not tolerate a dose of 500-5000U intravenous heparin at the time of transplant as determined by the transplant surgeon
  9. Patient who has a contraindication or allergy to or is expected to not tolerate a dose of 2500-7500U subcutaneous heparin prophylaxis three times daily during hospital stay as determined by the transplant surgeon
  10. Pregnant and breast feeding patients will be excluded from the study due to the small risk of radiation associated with the DTPA renal scan
  11. Patient body mass index (BMI) > 40
  12. Known anaphylactic reaction and/or angioedema to Premarin Intravenous therapy
  13. Presence of a condition or abnormality that in the opinion of the investigator or attending transplant surgeon primarily responsible for the patient's care would compromise the safety of the patient or the quality of the data

Sites / Locations

  • University of Pennsylvania

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Placebo Comparator

Arm Label

Active Arm

Placebo Arm

Arm Description

Participants randomized to the active arm will receive a single infusion of conjugated estrogens at the time of admission if within 8 hours of the expected surgery time or at approximately 8 hours to the expected surgery time if admission is earlier than that. Participants will then receive two daily infusions of conjugated estrogens after transplant given at 8 hours after reperfusion of the transplanted kidney and 24 hours after the first post transplant dose (32 hours after reperfusion of the transplanted kidney).

Participants randomized to the placebo arm will receive normal saline (0.9% sodium chloride) at the same rate as the active arm.

Outcomes

Primary Outcome Measures

Glomerular filtration rate (GFR)
GFR (glomerular filtration rate) as calculated from a DTPA (Diethylenetriamine Pentaacetic Acid, a medication) renal scan.

Secondary Outcome Measures

Delayed graft function (DGF)
Measurement of urine creatinine clearance and serum creatinine.

Full Information

First Posted
August 27, 2018
Last Updated
August 21, 2023
Sponsor
University of Pennsylvania
search

1. Study Identification

Unique Protocol Identification Number
NCT03663543
Brief Title
Intravenous Estrogen in Kidney Transplant Study
Acronym
PERT
Official Title
The Use of Peri-Operative Intravenous Estrogen for the Mitigation of Ischemia Reperfusion Injury in the Setting of Renal Transplantation
Study Type
Interventional

2. Study Status

Record Verification Date
August 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
August 26, 2016 (Actual)
Primary Completion Date
January 31, 2025 (Anticipated)
Study Completion Date
January 31, 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Pennsylvania

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Ischemia perfusion injury (IRI) is a major cause of organ injury during kidney transplantation. Currently there are no treatments for IRI other than dialysis. Preliminary studies in female mice have found protection from IRI when given short term estrogen supplements. This study will look at the effect of intravenous estrogen given peri-operatively to reduce the effect of IRI in female kidney transplant recipients.
Detailed Description
Ischemia-reperfusion injury (IRI) is a major etiology of organ injury and dysfunction that occurs during transplantation. In renal transplantation, the clinical manifestation of IRI is delayed graft function (DGF), typically defined as a recipient requiring dialysis within the first week after transplant. At present, there are no directed treatments for IRI associated with kidney transplantation and resultant DGF, other than supportive care with dialysis. This represents an unmet clinical need. While dialysis enables the support of patients until DGF resolves, DGF is associated with increased medical costs, increased length of hospital stay, increased rates of readmission to the hospital after transplantation, increased rates of rejection, and decreased graft survival. Therapies to reduce IRI might alleviate clinical complications associated with DGF, reduce costs associated with transplantation, and ease organ shortages by facilitating use of more marginal organs. Despite acceptance of gender disparities in IRI tolerance in animal systems, attempts to utilize hormonal manipulation in humans to achieve improved IRI tolerance have not been undertaken. In an effort to design such a translation, the investigators investigated if similar gender disparities exist in humans who have undergone kidney transplantation. After review of the United Network for Organ Sharing database, the investigators established that male recipient gender was highly associated with DGF. Then, the investigators demonstrated that manipulation of the pre-ischemic environment with short-term estrogen supplementation in female mice provides protection from renal IRI. As a logical next stop, the investigators propose hormonal manipulation with perioperative administration of intravenous conjugated estrogens as a novel therapeutic strategy to reduce the effect of IRI in female humans undergoing kidney transplantation. The investigators have designed an investigational new drug (IND) late phase I/early phase II prospective, single center, double blind, randomized, placebo-controlled trial to test the safety, feasibility, and efficacy of this therapy. If the administration of peri-operative intravenous administration has a positive impact on the rate of recovery of GFR after renal transplant and the inherent IRI, then this therapy would represent the first treatment for IRI and ultimately might reduce the incidence of DGF. Because DGF after kidney transplantation is associated with inferior transplant outcomes and increased costs,2 a therapy that mitigates the effect of IRI and consequently reduces the incidence of DGF not only might alleviate these complications but could also ease organ shortages by facilitating the use of more marginal organs. Moreover, if estrogen therapy does mitigate IRI in the setting of renal transplantation, it could be applied to other causes of renal IRI including supra-celiac clamping in trauma or vascular surgery or the use of cardiopulmonary bypass in cardiac surgery. Female adult subjects with a diagnosis of end stage renal disease who are dialysis dependent at the time of deceased donor renal transplantation and meet the inclusion and exclusion criteria will be eligible for participation in this study.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Ischemia Reperfusion Injury

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Parallel Assignment
Model Description
Parallel: Participants are assigned to one of two or more groups in parallel for the duration of the study
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
30 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Active Arm
Arm Type
Active Comparator
Arm Description
Participants randomized to the active arm will receive a single infusion of conjugated estrogens at the time of admission if within 8 hours of the expected surgery time or at approximately 8 hours to the expected surgery time if admission is earlier than that. Participants will then receive two daily infusions of conjugated estrogens after transplant given at 8 hours after reperfusion of the transplanted kidney and 24 hours after the first post transplant dose (32 hours after reperfusion of the transplanted kidney).
Arm Title
Placebo Arm
Arm Type
Placebo Comparator
Arm Description
Participants randomized to the placebo arm will receive normal saline (0.9% sodium chloride) at the same rate as the active arm.
Intervention Type
Drug
Intervention Name(s)
Conjugated Estrogen
Other Intervention Name(s)
Premarin
Intervention Description
Dosing of conjugated estrogen will be given pre kidney transplant procedure and twice after reperfusion of the transplanted kidney.
Intervention Type
Drug
Intervention Name(s)
Normal saline
Other Intervention Name(s)
0.9% sodium chloride
Intervention Description
Dosing of normal saline will be given pre kidney transplant procedure and twice after reperfusion of the transplanted kidney.
Primary Outcome Measure Information:
Title
Glomerular filtration rate (GFR)
Description
GFR (glomerular filtration rate) as calculated from a DTPA (Diethylenetriamine Pentaacetic Acid, a medication) renal scan.
Time Frame
Post-operative day three
Secondary Outcome Measure Information:
Title
Delayed graft function (DGF)
Description
Measurement of urine creatinine clearance and serum creatinine.
Time Frame
Immediately post-operative
Other Pre-specified Outcome Measures:
Title
Graft Failure
Description
Measurement of serum creatinine.
Time Frame
Post-operative day three and day ninety
Title
Post Op Day 3 Creatinine
Description
Measurement of serum creatinine and percent change from pre-transplant creatinine
Time Frame
Post-operative day 3
Title
Nadir Post op Day 90 Creatinine
Description
Measurement of serum creatinine and percent change from pre-transplant creatinine
Time Frame
post transplant day 90

10. Eligibility

Sex
Female
Gender Based
Yes
Gender Eligibility Description
Participants must be female
Minimum Age & Unit of Time
21 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Female gender Age > 21 years at time of transplant Pre-existing dialysis dependence of at least 1-months duration at the time of transplant Receiving a deceased donor renal transplant with KDPI >40 Written informed consent obtained from subject and ability for subject to comply with the requirements of the study Exclusion Criteria: History of solid organ transplant Receiving a combined heart-kidney transplant, liver-kidney transplant, or other multi- visceral organ transplant Personal history of deep vein thrombosis (DVT) or pulmonary embolism (PE) Personal history of hypercoagulable condition including but not limited to Lupus Anticoagulant, Leiden Factor V Mutation, Prothrombin Gene Mutation, Protein C or S deficiency, or any other hypercoagulable condition considered by the attending transplant surgeon on clinical service or Data and Safety Monitoring Board (DSMB) t to warrant exclusion from the study Personal history of an estrogen sensitive cancer (breast, endometrial, ovarian) Personal history of arterial thromboembolic disease such as stroke or myocardial infarction in the 6 months prior to transplantation Patient already on estrogen (including oral contraceptive pills) or anti-estrogen therapy for other indications Patient who is expected to not tolerate a dose of 500-5000U intravenous heparin at the time of transplant as determined by the transplant surgeon Patient who has a contraindication or allergy to or is expected to not tolerate a dose of 2500-7500U subcutaneous heparin prophylaxis three times daily during hospital stay as determined by the transplant surgeon Pregnant and breast feeding patients will be excluded from the study due to the small risk of radiation associated with the DTPA renal scan Patient body mass index (BMI) > 40 Known anaphylactic reaction and/or angioedema to Premarin Intravenous therapy Presence of a condition or abnormality that in the opinion of the investigator or attending transplant surgeon primarily responsible for the patient's care would compromise the safety of the patient or the quality of the data
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Matthew Levine, MD, PhD
Organizational Affiliation
University of Pennsylvania Health System
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Pennsylvania
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19104
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
21929642
Citation
Siedlecki A, Irish W, Brennan DC. Delayed graft function in the kidney transplant. Am J Transplant. 2011 Nov;11(11):2279-96. doi: 10.1111/j.1600-6143.2011.03754.x. Epub 2011 Sep 19.
Results Reference
background
PubMed Identifier
15950202
Citation
Kher A, Meldrum KK, Wang M, Tsai BM, Pitcher JM, Meldrum DR. Cellular and molecular mechanisms of sex differences in renal ischemia-reperfusion injury. Cardiovasc Res. 2005 Sep 1;67(4):594-603. doi: 10.1016/j.cardiores.2005.05.005.
Results Reference
background
PubMed Identifier
15614124
Citation
Kher A, Wang M, Tsai BM, Pitcher JM, Greenbaum ES, Nagy RD, Patel KM, Wairiuko GM, Markel TA, Meldrum DR. Sex differences in the myocardial inflammatory response to acute injury. Shock. 2005 Jan;23(1):1-10. doi: 10.1097/01.shk.0000148055.12387.15.
Results Reference
background
PubMed Identifier
17322926
Citation
Hedges SJ, Dehoney SB, Hooper JS, Amanzadeh J, Busti AJ. Evidence-based treatment recommendations for uremic bleeding. Nat Clin Pract Nephrol. 2007 Mar;3(3):138-53. doi: 10.1038/ncpneph0421.
Results Reference
background
PubMed Identifier
21164406
Citation
Wigginton JG, Pepe PE, Idris AH. Rationale for routine and immediate administration of intravenous estrogen for all critically ill and injured patients. Crit Care Med. 2010 Oct;38(10 Suppl):S620-9. doi: 10.1097/CCM.0b013e3181f243a9.
Results Reference
background
PubMed Identifier
26254516
Citation
Bradley LD, Gueye NA. The medical management of abnormal uterine bleeding in reproductive-aged women. Am J Obstet Gynecol. 2016 Jan;214(1):31-44. doi: 10.1016/j.ajog.2015.07.044. Epub 2015 Aug 5.
Results Reference
background
PubMed Identifier
23658207
Citation
Murray AW, Barnfield MC, Waller ML, Telford T, Peters AM. Assessment of glomerular filtration rate measurement with plasma sampling: a technical review. J Nucl Med Technol. 2013 Jun;41(2):67-75. doi: 10.2967/jnmt.113.121004. Epub 2013 May 8. Erratum In: J Nucl Med Technol. 2014 Dec;42(4):12A.
Results Reference
background
PubMed Identifier
9112349
Citation
Ojo AO, Wolfe RA, Held PJ, Port FK, Schmouder RL. Delayed graft function: risk factors and implications for renal allograft survival. Transplantation. 1997 Apr 15;63(7):968-74. doi: 10.1097/00007890-199704150-00011.
Results Reference
result
PubMed Identifier
21274961
Citation
Alves MG, Oliveira PJ, Carvalho RA. Substrate selection in hearts subjected to ischemia/reperfusion: role of cardioplegic solutions and gender. NMR Biomed. 2011 Nov;24(9):1029-37. doi: 10.1002/nbm.1640. Epub 2011 Jan 28.
Results Reference
result
PubMed Identifier
22572084
Citation
Ardelt AA, Carpenter RS, Lobo MR, Zeng H, Solanki RB, Zhang A, Kulesza P, Pike MM. Estradiol modulates post-ischemic cerebral vascular remodeling and improves long-term functional outcome in a rat model of stroke. Brain Res. 2012 Jun 21;1461:76-86. doi: 10.1016/j.brainres.2012.04.024. Epub 2012 Apr 21.
Results Reference
result
PubMed Identifier
12219027
Citation
Eckhoff DE, Bilbao G, Frenette L, Thompson JA, Contreras JL. 17-Beta-estradiol protects the liver against warm ischemia/reperfusion injury and is associated with increased serum nitric oxide and decreased tumor necrosis factor-alpha. Surgery. 2002 Aug;132(2):302-9. doi: 10.1067/msy.2002.125718.
Results Reference
result
PubMed Identifier
15698835
Citation
Gabel SA, Walker VR, London RE, Steenbergen C, Korach KS, Murphy E. Estrogen receptor beta mediates gender differences in ischemia/reperfusion injury. J Mol Cell Cardiol. 2005 Feb;38(2):289-97. doi: 10.1016/j.yjmcc.2004.11.013. Epub 2005 Jan 20.
Results Reference
result
PubMed Identifier
21398592
Citation
Peng X, Wang J, Lassance-Soares RM, Najafi AH, Sood S, Aghili N, Alderman LO, Panza JA, Faber JE, Wang S, Epstein SE, Burnett MS. Gender differences affect blood flow recovery in a mouse model of hindlimb ischemia. Am J Physiol Heart Circ Physiol. 2011 Jun;300(6):H2027-34. doi: 10.1152/ajpheart.00004.2011. Epub 2011 Mar 11.
Results Reference
result
PubMed Identifier
19638737
Citation
Hu H, Wang G, Batteux F, Nicco C. Gender differences in the susceptibility to renal ischemia-reperfusion injury in BALB/c mice. Tohoku J Exp Med. 2009 Aug;218(4):325-9. doi: 10.1620/tjem.218.325.
Results Reference
result
PubMed Identifier
10231466
Citation
Muller V, Szabo A, Viklicky O, Gaul I, Portl S, Philipp T, Heemann UW. Sex hormones and gender-related differences: their influence on chronic renal allograft rejection. Kidney Int. 1999 May;55(5):2011-20. doi: 10.1046/j.1523-1755.1999.00441.x.
Results Reference
result
PubMed Identifier
12234307
Citation
Muller V, Losonczy G, Heemann U, Vannay A, Fekete A, Reusz G, Tulassay T, Szabo AJ. Sexual dimorphism in renal ischemia-reperfusion injury in rats: possible role of endothelin. Kidney Int. 2002 Oct;62(4):1364-71. doi: 10.1111/j.1523-1755.2002.kid590.x.
Results Reference
result
PubMed Identifier
15358759
Citation
Park KM, Kim JI, Ahn Y, Bonventre AJ, Bonventre JV. Testosterone is responsible for enhanced susceptibility of males to ischemic renal injury. J Biol Chem. 2004 Dec 10;279(50):52282-92. doi: 10.1074/jbc.M407629200. Epub 2004 Sep 8.
Results Reference
result
PubMed Identifier
15670785
Citation
Park KM, Cho HJ, Bonventre JV. Orchiectomy reduces susceptibility to renal ischemic injury: a role for heat shock proteins. Biochem Biophys Res Commun. 2005 Mar 4;328(1):312-7. doi: 10.1016/j.bbrc.2004.12.177.
Results Reference
result
PubMed Identifier
21658244
Citation
Robert R, Ghazali DA, Favreau F, Mauco G, Hauet T, Goujon JM. Gender difference and sex hormone production in rodent renal ischemia reperfusion injury and repair. J Inflamm (Lond). 2011 Jun 9;8:14. doi: 10.1186/1476-9255-8-14.
Results Reference
result
PubMed Identifier
21691090
Citation
Rusai K, Prokai A, Szebeni B, Meszaros K, Fekete A, Szalay B, Vannay A, Degrell P, Muller V, Tulassay T, Szabo AJ. Gender differences in serum and glucocorticoid regulated kinase-1 (SGK-1) expression during renal ischemia/reperfusion injury. Cell Physiol Biochem. 2011;27(6):727-38. doi: 10.1159/000330081. Epub 2011 Jun 17.
Results Reference
result
PubMed Identifier
17336333
Citation
Shen SQ, Zhang Y, Xiong CL. The protective effects of 17beta-estradiol on hepatic ischemia-reperfusion injury in rat model, associated with regulation of heat-shock protein expression. J Surg Res. 2007 Jun 1;140(1):67-76. doi: 10.1016/j.jss.2006.10.022. Epub 2007 Mar 2.
Results Reference
result
PubMed Identifier
23552495
Citation
Soljancic A, Ruiz AL, Chandrashekar K, Maranon R, Liu R, Reckelhoff JF, Juncos LA. Protective role of testosterone in ischemia-reperfusion-induced acute kidney injury. Am J Physiol Regul Integr Comp Physiol. 2013 Jun 1;304(11):R951-8. doi: 10.1152/ajpregu.00360.2012. Epub 2013 Apr 3.
Results Reference
result
PubMed Identifier
15251365
Citation
Wittnich C, Belanger MP, Askin N, Boscarino C, Wallen WJ. Lower liver transplant success in females: gender differences in metabolic response to global ischemia. Transplant Proc. 2004 Jun;36(5):1485-8. doi: 10.1016/j.transproceed.2004.05.055.
Results Reference
result
PubMed Identifier
15618244
Citation
Antus B, Liu S, Yao Y, Zou H, Song E, Lutz J, Heemann U. Effects of progesterone and selective oestrogen receptor modulators on chronic allograft nephropathy in rats. Nephrol Dial Transplant. 2005 Feb;20(2):329-35. doi: 10.1093/ndt/gfh602. Epub 2004 Dec 23.
Results Reference
result
PubMed Identifier
12389082
Citation
Antus B, Yao Y, Song E, Liu S, Lutz J, Heemann U. Opposite effects of testosterone and estrogens on chronic allograft nephropathy. Transpl Int. 2002 Oct;15(9-10):494-501. doi: 10.1007/s00147-002-0449-2. Epub 2002 Sep 20.
Results Reference
result
PubMed Identifier
27088798
Citation
Aufhauser DD Jr, Wang Z, Murken DR, Bhatti TR, Wang Y, Ge G, Redfield RR 3rd, Abt PL, Wang L, Svoronos N, Thomasson A, Reese PP, Hancock WW, Levine MH. Improved renal ischemia tolerance in females influences kidney transplantation outcomes. J Clin Invest. 2016 May 2;126(5):1968-77. doi: 10.1172/JCI84712. Epub 2016 Apr 18.
Results Reference
result
PubMed Identifier
3018561
Citation
Livio M, Mannucci PM, Vigano G, Mingardi G, Lombardi R, Mecca G, Remuzzi G. Conjugated estrogens for the management of bleeding associated with renal failure. N Engl J Med. 1986 Sep 18;315(12):731-5. doi: 10.1056/NEJM198609183151204.
Results Reference
result
PubMed Identifier
1963650
Citation
Heistinger M, Stockenhuber F, Schneider B, Pabinger I, Brenner B, Wagner B, Balcke P, Lechner K, Kyrle PA. Effect of conjugated estrogens on platelet function and prostacyclin generation in CRF. Kidney Int. 1990 Dec;38(6):1181-6. doi: 10.1038/ki.1990.331.
Results Reference
result
PubMed Identifier
2850395
Citation
Vigano G, Gaspari F, Locatelli M, Pusineri F, Bonati M, Remuzzi G. Dose-effect and pharmacokinetics of estrogens given to correct bleeding time in uremia. Kidney Int. 1988 Dec;34(6):853-8. doi: 10.1038/ki.1988.260.
Results Reference
result
PubMed Identifier
6281704
Citation
DeVore GR, Owens O, Kase N. Use of intravenous Premarin in the treatment of dysfunctional uterine bleeding--a double-blind randomized control study. Obstet Gynecol. 1982 Mar;59(3):285-91.
Results Reference
result

Learn more about this trial

Intravenous Estrogen in Kidney Transplant Study

We'll reach out to this number within 24 hrs